Ketanest (Esketamine Hydrochloride)

Esketamine acts as a high‑affinity antagonist of the N‑methyl‑D‑aspartate (NMDA) receptor in the central nervous system. By blocking this excitatory glutamate receptor, it reduces neuronal firing, producing dissociative anesthesia, analgesia, and a loss of consciousness. The effect is rapid, typically within minutes after intravenous or intramuscular administration.

The specific dose of Ketanest is determined by the treating physician based on the patient’s age, weight, clinical condition, and the intended procedure. Dosing is individualized and administered by qualified healthcare professionals in a controlled setting such as an operating room or procedural suite.

Safety data for esketamine during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and only under specialist supervision.

To request Ketanest, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Compared with traditional intravenous anesthetics such as propofol, esketamine provides dissociative anesthesia with strong analgesic properties and tends to preserve airway reflexes and cardiovascular stability. However, it may cause psychotomimetic effects and hypertension, which are less common with agents like propofol. Choice of agent depends on the clinical scenario and patient factors.

Ketanest should be stored refrigerated at 2 °C to 8 °C, protected from light, and must not be frozen or shaken. Vials should remain in their original packaging until use, and any unused portion should be discarded according to local regulations for controlled substances.

Ketanest is supplied as a sterile injectable solution for intramuscular or intravenous injection. Administration is performed by a qualified clinician, who selects the appropriate route, dose, and rate based on the procedure and patient condition. Continuous monitoring of vital signs is required throughout the administration and recovery phases.

The most serious risks include respiratory depression, severe hypertension, and psychotomimetic reactions such as hallucinations or agitation. Rarely, anaphylactic reactions or increased intracranial pressure may occur. Prompt recognition and supportive measures, including airway management and blood pressure control, are essential to mitigate these risks.

Ketanest is contraindicated in patients with known hypersensitivity to esketamine or any component of the formulation. It should be avoided in individuals with uncontrolled hypertension, severe cardiovascular disease, elevated intracranial pressure, or a history of psychotic disorders unless the benefits clearly outweigh the risks. Use in pediatric patients is limited to specific, supervised settings.